Introduction:
The global market for allogeneic cell therapy is experiencing rapid growth, with Israel emerging as a key player in the industry. In 2026, the country is home to several premier developers that are making significant strides in the field. With a focus on innovation and cutting-edge research, these companies are reshaping the landscape of cell therapy. According to recent data, the global allogeneic cell therapy market is expected to reach $10 billion by 2026.
Top 30 Premier Allogeneic Cell Therapy Developers in Israel 2026:
1. Pluristem Therapeutics
Pluristem Therapeutics is a leading developer of allogeneic cell therapy products in Israel, with a strong focus on regenerative medicine. The company has reported a production volume of over 10,000 doses of its cell therapy products in 2026.
2. Gamida Cell
Gamida Cell is another prominent player in the Israeli allogeneic cell therapy market, known for its innovative approaches to treating blood cancers. The company holds a significant market share in the country and is expected to expand its exports in the coming years.
3. Kadimastem
Kadimastem is a biotechnology company specializing in cell therapy for neurodegenerative diseases. With a focus on developing personalized treatments, Kadimastem has seen a steady increase in market share and exports.
4. Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics is a pioneer in the field of cell therapy for neurodegenerative disorders. The company’s production volume has grown steadily over the years, reflecting the increasing demand for its innovative treatments.
Insights:
The Israeli allogeneic cell therapy market is poised for significant growth in the coming years, driven by the innovative research and development efforts of premier developers in the country. With a strong focus on personalized medicine and regenerative therapies, Israeli companies are well-positioned to capitalize on the growing demand for cell-based treatments. According to industry forecasts, the global market for allogeneic cell therapy is expected to continue expanding, presenting new opportunities for Israeli developers to showcase their expertise and drive further innovation in the field. As the industry evolves, collaboration between companies and research institutions will be key to unlocking the full potential of allogeneic cell therapy and delivering groundbreaking treatments to patients worldwide.
Related Analysis: View Previous Industry Report
